Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10850031 | 0.90 | MAPT (0.44) | MAPTPOLBRAB9ACES2CES1 | |
| SCHEMBL5747385 | 0.87 | MMP8 (0.43) | MAPTPOLBRAB9ACYP1A2MEN1 | |
| SCHEMBL13228115 | 0.86 | MAPT (0.41) | MAPTPOLBRAB9ACES2CES1 | |
| SCHEMBL8229151 | 0.85 | CES2 (0.55) | MAPTPOLBRAB9ACES2CES1 | |
| SCHEMBL7942217 | 0.84 | MAPT (0.45) | MAPTPOLBRAB9ACES2CES1 | |
| SCHEMBL25117945 | 0.84 | CYP3A4 (0.42) | MAPTMEN1KMT2ALMNACYP2C9 | |
| SCHEMBL17168993 | 0.84 | MAPT (0.44) | MAPTPOLBRAB9ACES2CES1 | |
| SCHEMBL19183203 | 0.84 | MAPT (0.44) | MAPTPOLBRAB9ACES2CES1 | |
| SCHEMBL5593462 | 0.84 | NR3C2 (0.47) | TSHR | |
| SCHEMBL31198063 | 0.83 | MAPT (0.43) | MAPTPOLBRAB9ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023078267-A1 | AMINO-CONTAINING MACROCYCLIC COMPOUND AS PROTEIN KINASE MODULATOR | 赛诺哈勃药业（成都）有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078267-A1 | AMINO-CONTAINING MACROCYCLIC COMPOUND AS PROTEIN KINASE MODULATOR | 赛诺哈勃药业（成都）有限公司 | 2023-05-11 | — | — | WO | disclosed |
| CN-116063326-A | Amino-containing macrocyclic compounds as protein kinase modulators | 赛诺哈勃药业（成都）有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-9546138-B2 | Pyridone derivatives and uses thereof in the treatment of tuberculosis | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| EP-2931716-B1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2016-11-02 | — | — | EP | disclosed |
| US-20150291526-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
| WO-2014093606-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| EP-0318214-B1 | Tri- and tetra-substituted-oxetanes and -tetrahydrofurans and intermediates thereof | SCHERING CORP (US) | 1994-12-14 | — | — | EP | disclosed |
| US-5039676-A | Fungicide, antiallergens | SCHERING CORPORATION (US) | 1991-08-13 | — | — | US | disclosed |
| EP-0386143-A1 | TRI- AND TETRA-SUBSTITUTED-OXETANES AND TETRAHYDROFURANS AND INTERMEDIATES THEREOF | SCHERING CORPORATION (US) | 1990-09-12 | — | — | EP | disclosed |
| WO-1989004829-A1 | TRI- AND TETRA-SUBSTITUTED-OXETANES AND TETRAHYDROFURANS AND INTERMEDIATES THEREOF | SCHERING CORPORATION (US) | 1989-06-01 | — | — | WO | disclosed |
| EP-0318214-A1 | Tri- and tetra-substituted-oxetanes and -tetrahydrofurans and intermediates thereof | SCHERING CORPORATION (US) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291526-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | COASY, PLPBP, ACSS2 | MAPT 2624/4885POLB 2995/4885RAB9A 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.